I realize that NBOMe threads are a dime-a-dozen here, but I didn't see one for this species, and I hope to get some information on it before trying it out.
It hasn't been listed yet in the NBOMe Comparison Thread:
...so there is not much to go on.
My general question is for advice on dosing, timing of effects and degree of "bodyload".
Specifically, my question/concern is the following:
I have read a few times here and elsewhere that the 2C-X-NBOMe series potency is REVERSED relative to that of the original 2C-X series. Thus, 2C-P has a bulky propyl substitution at the 4-position and is more potent than 2C-E (which has a smaller 4-position substitution), and 2C-E is in turn more potent than 2C-D with a minuscule 4-position methyl substitution.
Any feedback on this point? It really seems like supposition at this point.
If this is the case, then 2C-iP-NBOMe should be among the least potent of the NBOMe series. Of course the charge density and polarity will be completely opposite, but bulk-wise, I imagine that the isopropyl substitution at the 4-position of 2C-iP-NBOMe is about the same size as the nitro functionality of 2C-N-NBOMe: Can anyone chime in with an agreement or refutation?
Thanks for any insights fellow BLers! Of course, in the absence of any feedback, dosing schedule will likely start at ~10 ug with ~ 1 week between incidences. Vasoconstriction (ala BDF) is the biggest concern at this point.